BACKGROUND: Biomarkers of progression from latent Mycobacterium tuberculosis infection to active tuberculosis are needed. We assessed correlations between infection outcome and antibody responses in macaques and humans by high-throughput, proteome-scale serological studies. METHODS: Mycobacterium tuberculosis proteome microarrays were probed with serial sera from macaques representing various infection outcomes and with single-point human sera from tuberculosis suspects. Fluorescence intensity data were analyzed by calculating Z scores and associated P values. Temporal changes in macaque antibody responses were analyzed by polynomial regression. Correlations between human responses and sputum bacillary burden were assessed by quantile and hurdle regression. RESULTS: Macaque outcome groups exhibited distinct antibody profiles: early, transient responses in latent infection and stable antibody increase in active and reactivation disease. In humans, antibody levels and reactive protein numbers increased with bacillary burden. Responses to a subset of 10 proteins were more tightly associated with disease state than reactivity to the broader reactive proteome. CONCLUSIONS: Integration of macaque and human data reveals dynamic properties of antibody responses in relation to outcome and leads to actionable findings for translational research. These include the potential of antibody responses to detect acute infection and preclinical tuberculosis and to identify serodiagnostic proteins for the spectrum of bacillary burden in tuberculosis.
BACKGROUND: Biomarkers of progression from latent Mycobacterium tuberculosis infection to active tuberculosis are needed. We assessed correlations between infection outcome and antibody responses in macaques and humans by high-throughput, proteome-scale serological studies. METHODS:Mycobacterium tuberculosis proteome microarrays were probed with serial sera from macaques representing various infection outcomes and with single-point human sera from tuberculosis suspects. Fluorescence intensity data were analyzed by calculating Z scores and associated P values. Temporal changes in macaque antibody responses were analyzed by polynomial regression. Correlations between human responses and sputum bacillary burden were assessed by quantile and hurdle regression. RESULTS: Macaque outcome groups exhibited distinct antibody profiles: early, transient responses in latent infection and stable antibody increase in active and reactivation disease. In humans, antibody levels and reactive protein numbers increased with bacillary burden. Responses to a subset of 10 proteins were more tightly associated with disease state than reactivity to the broader reactive proteome. CONCLUSIONS: Integration of macaque and human data reveals dynamic properties of antibody responses in relation to outcome and leads to actionable findings for translational research. These include the potential of antibody responses to detect acute infection and preclinical tuberculosis and to identify serodiagnostic proteins for the spectrum of bacillary burden in tuberculosis.
Authors: Shelby L O'Connor; Alex J Blasky; Chad J Pendley; Ericka A Becker; Roger W Wiseman; Julie A Karl; Austin L Hughes; David H O'Connor Journal: Immunogenetics Date: 2007-03-24 Impact factor: 2.846
Authors: Benjamin J Burwitz; Chad J Pendley; Justin M Greene; Ann M Detmer; Jennifer J Lhost; Julie A Karl; Shari M Piaskowski; Richard A Rudersdorf; Lyle T Wallace; Benjamin N Bimber; John T Loffredo; Daryl G Cox; Wilfried Bardet; William Hildebrand; Roger W Wiseman; Shelby L O'Connor; David H O'Connor Journal: J Virol Date: 2009-04-01 Impact factor: 5.103
Authors: D Huw Davies; Xiaowu Liang; Jenny E Hernandez; Arlo Randall; Siddiqua Hirst; Yunxiang Mu; Kimberly M Romero; Toai T Nguyen; Mina Kalantari-Dehaghi; Shane Crotty; Pierre Baldi; Luis P Villarreal; Philip L Felgner Journal: Proc Natl Acad Sci U S A Date: 2005-01-12 Impact factor: 11.205
Authors: Sylvie Bertholet; Gregory C Ireton; Maria Kahn; Jeffrey Guderian; Raodoh Mohamath; Nicole Stride; Elsa M Laughlin; Susan L Baldwin; Thomas S Vedvick; Rhea N Coler; Steven G Reed Journal: J Immunol Date: 2008-12-01 Impact factor: 5.422
Authors: Bareng A S Nonyane; Mark P Nicol; Nicholas J Andreas; Stefanie Rimmele; Nicole Schneiderhan-Marra; Lesley J Workman; Mark D Perkins; Thomas Joos; Tobias Broger; Jerrold J Ellner; David Alland; Beate Kampmann; Susan E Dorman; Heather J Zar Journal: Pediatr Infect Dis J Date: 2018-01 Impact factor: 2.129
Authors: Kaustuv Nayak; Lichen Jing; Ronnie M Russell; D Huw Davies; Gary Hermanson; Douglas M Molina; Xiaowu Liang; David R Sherman; William W Kwok; Junbao Yang; John Kenneth; Syed F Ahamed; Anmol Chandele; Kaja Murali-Krishna; David M Koelle Journal: Tuberculosis (Edinb) Date: 2015-03-27 Impact factor: 3.131
Authors: André Kübler; Brian Luna; Christer Larsson; Nicole C Ammerman; Bruno B Andrade; Marlene Orandle; Kevin W Bock; Ziyue Xu; Ulas Bagci; Daniel J Mollura; John Marshall; Jay Burns; Kathryn Winglee; Bintou Ahmadou Ahidjo; Laurene S Cheung; Mariah Klunk; Sanjay K Jain; Nathella Pavan Kumar; Subash Babu; Alan Sher; Jon S Friedland; Paul T G Elkington; William R Bishai Journal: J Pathol Date: 2014-10-06 Impact factor: 7.996
Authors: John P Bannantine; Joseph J Campo; Lingling Li; Arlo Randall; Jozelyn Pablo; Craig A Praul; Juan Antonio Raygoza Garay; Judith R Stabel; Vivek Kapur Journal: Clin Vaccine Immunol Date: 2017-07-05
Authors: Konstantin P Lyashchenko; Adrian Grandison; Karen Keskinen; Alina Sikar-Gang; Paul Lambotte; Javan Esfandiari; Gregory C Ireton; Aarthy Vallur; Steven G Reed; Gareth Jones; H Martin Vordermeier; Judy R Stabel; Tyler C Thacker; Mitchell V Palmer; W Ray Waters Journal: Clin Vaccine Immunol Date: 2017-12-05